Expanded access to TAK-881 for primary immunodeficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This program offers continued access to the study drug TAK-881 for people with primary immunodeficiency diseases who have already completed a related study. It is designed for those who are benefiting from the treatment and have no safety concerns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a primary immunodeficiency disease and have finished the final visit of the study TAK-881-3002.
- Your doctor must agree that you are still getting benefit from TAK-881.
- You (or your parent or guardian) must understand the program and sign a consent form.
- You cannot have any medical condition or lab result that your doctor thinks could make the treatment unsafe.
- You must not have a known allergy to TAK-881 or any of its ingredients.
- If you could become pregnant, you must agree to use highly effective birth control during the program. You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
This trial tests a new medication called TAK-188 for people with certain advanced solid tumors that have not responded to standard therapies, including checkpoint inhibitors. It aims to see if TAK-188 can help shrink or control the cancer.
This study tests an investigational drug called TAK-781 in healthy volunteers and in people with primary sclerosing cholangitis (PSC) who do not have cirrhosis. The study aims to see how the drug is processed by the body and whether it is safe.
This trial tests a new intravenous immunoglobulin (IVIG) treatment for patients with primary immunodeficiency diseases, such as common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA). It aims to see if this medicine is safe and works well to prevent infections.
This study collects blood (and sometimes related samples) to learn how genes and the immune system work in people with primary immunodeficiency (PID) or in family members who may not have it. The goal is to improve understanding of rare immune conditions and help guide future care.
This study tests a medication called tofacitinib that modulates the immune system in children and young adults with Down syndrome aged 6–22 years. The goal is to see if it can improve brain development and overall health outcomes over 6 months.
Hear when a new Primary Immunodeficiency Diseases (PIDD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.